Search Results
Search for other papers by Takuya Mikoshiba in
Google Scholar
PubMed
Search for other papers by Mariko Sekimizu in
Google Scholar
PubMed
Search for other papers by Shin Saito in
Google Scholar
PubMed
Search for other papers by Shintaro Nakamura in
Google Scholar
PubMed
Search for other papers by Ryoto Nagai in
Google Scholar
PubMed
Search for other papers by Miho Kawaida in
Google Scholar
PubMed
Department of Endocrinology, Metabolism and Nephrology, Keio University School of Medicine, Shinanomachi, Shinjuku-ku, Tokyo, Japan
Search for other papers by Isao Kurihara in
Google Scholar
PubMed
Department of Endocrinology, Metabolism and Nephrology, NHO Tokyo Medical Center, Higashigaoka, Meguro-ku, Tokyo, Japan
Search for other papers by Sakiko Kobayashi in
Google Scholar
PubMed
Search for other papers by Hiroyuki Ozawa in
Google Scholar
PubMed
& Azcutia 2019 , Zhou et al. 2019 , Chung et al. 2020 , Abe et al. 2021 ). Most are described in the form of case reports, and only a few reports reviewed many cases ( Kunc et al. 2015 ). Therefore, its prevalence has not yet been clarified
Search for other papers by Arivarasan Karunamurthy in
Google Scholar
PubMed
Search for other papers by Federica Panebianco in
Google Scholar
PubMed
Search for other papers by Susan J Hsiao in
Google Scholar
PubMed
Search for other papers by Jennie Vorhauer in
Google Scholar
PubMed
Search for other papers by Marina N Nikiforova in
Google Scholar
PubMed
Search for other papers by Simion Chiosea in
Google Scholar
PubMed
Search for other papers by Yuri E Nikiforov in
Google Scholar
PubMed
also reported EIF1AX mutations in anaplastic thyroid carcinomas (ATC) ( Kunstman et al. 2015 ). However, the prevalence of these mutations in other common types of thyroid cancer, such as follicular carcinoma, and in benign thyroid nodules remains
Institute of Clinical Research, University of Southern Denmark, Odense, Denmark
Search for other papers by Jes Sloth Mathiesen in
Google Scholar
PubMed
Search for other papers by Jens Peter Kroustrup in
Google Scholar
PubMed
Search for other papers by Peter Vestergaard in
Google Scholar
PubMed
Search for other papers by Mette Madsen in
Google Scholar
PubMed
Search for other papers by Kirstine Stochholm in
Google Scholar
PubMed
Search for other papers by Per Løgstrup Poulsen in
Google Scholar
PubMed
Search for other papers by Åse Krogh Rasmussen in
Google Scholar
PubMed
Search for other papers by Ulla Feldt-Rasmussen in
Google Scholar
PubMed
Search for other papers by Sten Schytte in
Google Scholar
PubMed
Search for other papers by Henrik Baymler Pedersen in
Google Scholar
PubMed
Search for other papers by Christoffer Holst Hahn in
Google Scholar
PubMed
Search for other papers by Jens Bentzen in
Google Scholar
PubMed
Search for other papers by Mette Gaustadnes in
Google Scholar
PubMed
Search for other papers by Torben Falck Ørntoft in
Google Scholar
PubMed
Search for other papers by Thomas van Overeem Hansen in
Google Scholar
PubMed
Search for other papers by Finn Cilius Nielsen in
Google Scholar
PubMed
Search for other papers by Kim Brixen in
Google Scholar
PubMed
Department of Clinical Genetics, Odense University Hospital, Odense, Denmark
Search for other papers by Anja Lisbeth Frederiksen in
Google Scholar
PubMed
Search for other papers by Christian Godballe in
Google Scholar
PubMed
alive at April 21, 2012, yielding a point prevalence of 1.65 per million ( Znaczko et al . 2014 ). However, it is unclear if this is representative of larger populations. A German study reported an MEN2B incidence (M918T carriers only) of 1.4 per
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, University of Tübingen, Tübingen, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Stefan Zoltán Lutz in
Google Scholar
PubMed
Search for other papers by Tilman Todenhöfer in
Google Scholar
PubMed
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, University of Tübingen, Tübingen, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Robert Wagner in
Google Scholar
PubMed
Search for other papers by Jörg Hennenlotter in
Google Scholar
PubMed
Search for other papers by Jana Marlene Ferchl in
Google Scholar
PubMed
Search for other papers by Marcus Oliver Scharpf in
Google Scholar
PubMed
Search for other papers by Peter Martus in
Google Scholar
PubMed
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Institute of Pharmaceutical Sciences, Department of Pharmacy and Biochemistry, University of Tübingen, Tübingen, Germany
Search for other papers by Harald Staiger in
Google Scholar
PubMed
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, University of Tübingen, Tübingen, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Andreas Fritsche in
Google Scholar
PubMed
Search for other papers by Arnulf Stenzl in
Google Scholar
PubMed
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, University of Tübingen, Tübingen, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Hans-Ulrich Häring in
Google Scholar
PubMed
Institute for Diabetes Research and Metabolic Diseases (IDM) of the Helmholtz Center Munich, University of Tübingen, Tübingen, Germany
German Center for Diabetes Research (DZD), Munich-Neuherberg, Germany
Search for other papers by Martin Heni in
Google Scholar
PubMed
be higher in diabetes ( Giovannucci et al . 2010 ). However, studies reported that incidence of PCa is not increased in men with type 2 diabetes, some studies even found reduced prevalence ( Kasper et al . 2009 ). In contrast, PCa survival is
Search for other papers by J Di Cristofaro in
Google Scholar
PubMed
Search for other papers by V Vasko in
Google Scholar
PubMed
Search for other papers by V Savchenko in
Google Scholar
PubMed
Search for other papers by S Cherenko in
Google Scholar
PubMed
Search for other papers by A Larin in
Google Scholar
PubMed
Search for other papers by M D Ringel in
Google Scholar
PubMed
Search for other papers by M Saji in
Google Scholar
PubMed
Search for other papers by M Marcy in
Google Scholar
PubMed
Search for other papers by J F Henry in
Google Scholar
PubMed
Search for other papers by P Carayon in
Google Scholar
PubMed
Search for other papers by C De Micco in
Google Scholar
PubMed
and Brest regions ( Prisyazhiuk et al. 1991 , Baverstock et al. 1992 ). In Belarus, the prevalence of pediatric cancer peaked in 1995 and thereafter decreased gradually while that of adolescent thyroid cancer increased ( Demidchik et al. 2002
Search for other papers by Seo Ki Kim in
Google Scholar
PubMed
Search for other papers by Jung-Woo Woo in
Google Scholar
PubMed
Search for other papers by Jun Ho Lee in
Google Scholar
PubMed
Search for other papers by Inhye Park in
Google Scholar
PubMed
Search for other papers by Jun-Ho Choe in
Google Scholar
PubMed
Search for other papers by Jung-Han Kim in
Google Scholar
PubMed
Search for other papers by Jee Soo Kim in
Google Scholar
PubMed
thyroiditis; PTC, papillary thyroid carcinoma; ETE, extrathyroidal extension; CLNM, central lymph node metastasis. CLT was an independent predictor for low prevalence of ETE in both BRAF-negative and BRAF-positive conventional PTC patients As seen in Table 2
Search for other papers by L Fugazzola in
Google Scholar
PubMed
Search for other papers by E Puxeddu in
Google Scholar
PubMed
Search for other papers by N Avenia in
Google Scholar
PubMed
Search for other papers by C Romei in
Google Scholar
PubMed
Search for other papers by V Cirello in
Google Scholar
PubMed
Search for other papers by A Cavaliere in
Google Scholar
PubMed
Search for other papers by P Faviana in
Google Scholar
PubMed
Search for other papers by D Mannavola in
Google Scholar
PubMed
Search for other papers by S Moretti in
Google Scholar
PubMed
Search for other papers by S Rossi in
Google Scholar
PubMed
Search for other papers by M Sculli in
Google Scholar
PubMed
Search for other papers by V Bottici in
Google Scholar
PubMed
Search for other papers by P Beck-Peccoz in
Google Scholar
PubMed
Search for other papers by F Pacini in
Google Scholar
PubMed
Search for other papers by A Pinchera in
Google Scholar
PubMed
Search for other papers by F Santeusanio in
Google Scholar
PubMed
Search for other papers by R Elisei in
Google Scholar
PubMed
seems to play a very central role in the pathogenesis of this tumor. B-RAF mutations have been described at high frequency in melanoma (70%) and, with a lower prevalence (10–20%), also in colon and ovarian cancer, in lung and stomach cancer and
Search for other papers by Birke Bausch in
Google Scholar
PubMed
Search for other papers by Ulrich Wellner in
Google Scholar
PubMed
Search for other papers by Dirk Bausch in
Google Scholar
PubMed
Search for other papers by Francesca Schiavi in
Google Scholar
PubMed
Search for other papers by Marta Barontini in
Google Scholar
PubMed
Search for other papers by Gabriela Sanso in
Google Scholar
PubMed
Search for other papers by Martin K Walz in
Google Scholar
PubMed
Search for other papers by Mariola Peczkowska in
Google Scholar
PubMed
Search for other papers by Georges Weryha in
Google Scholar
PubMed
Search for other papers by Patrizia Dall'Igna in
Google Scholar
PubMed
Search for other papers by Giovanni Cecchetto in
Google Scholar
PubMed
Search for other papers by Gianni Bisogno in
Google Scholar
PubMed
Search for other papers by Lars C Moeller in
Google Scholar
PubMed
Search for other papers by Detlef Bockenhauer in
Google Scholar
PubMed
Search for other papers by Attila Patocs in
Google Scholar
PubMed
Search for other papers by Karoly Rácz in
Google Scholar
PubMed
Search for other papers by Dmitry Zabolotnyi in
Google Scholar
PubMed
Search for other papers by Svetlana Yaremchuk in
Google Scholar
PubMed
Search for other papers by Iveta Dzivite-Krisane in
Google Scholar
PubMed
Search for other papers by Frederic Castinetti in
Google Scholar
PubMed
Search for other papers by David Taieb in
Google Scholar
PubMed
Search for other papers by Angelica Malinoc in
Google Scholar
PubMed
Search for other papers by Ernst von Dobschuetz in
Google Scholar
PubMed
Search for other papers by Jochen Roessler in
Google Scholar
PubMed
Search for other papers by Kurt W Schmid in
Google Scholar
PubMed
Search for other papers by Giuseppe Opocher in
Google Scholar
PubMed
Search for other papers by Charis Eng in
Google Scholar
PubMed
Search for other papers by Hartmut P H Neumann in
Google Scholar
PubMed
et al . 1990 , Ciftci et al . 2001 , Barontini et al . 2006 ). Prevalence of hereditary and malignant tumors is controversial, but of utmost importance for quality-of-life considerations and survivorship ( Ross 2000 , Barontini et al . 2006
Search for other papers by Achim Fleischmann in
Google Scholar
PubMed
Search for other papers by Beatrice Waser in
Google Scholar
PubMed
Search for other papers by Jean Claude Reubi in
Google Scholar
PubMed
]-bombesin(6–14) as radioligands for GRP-receptors. Information about prevalence and quantity of GRP-receptor expressing tumor vessels and density of expressed GRP-receptors in these frequent cancers is particularly important to determine the potential value
Search for other papers by Francis Worden in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Martin Fassnacht in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Yuankai Shi in
Google Scholar
PubMed
Search for other papers by Tatiana Hadjieva in
Google Scholar
PubMed
Search for other papers by Françoise Bonichon in
Google Scholar
PubMed
Search for other papers by Ming Gao in
Google Scholar
PubMed
Division of Hematology/Oncology, Endocrine Unit, Comprehensive Cancer Center Mainfranken, Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Radiotherapy Department, Institut Bergonie, Tianjin Medical University Cancer Hospital, Fondazione IRCCS Ca' Granda, Department of Pathophysiology and Transplantation, Nagoya University Hospital, Aichi Cancer Center Hospital, Seoul National University College of Medicine, Asan Medicine Center, Department of Internal Medicine, Bayer HealthCare Pharmaceuticals, Bayer Pharma AG, Institut Gustave Roussy, Department of Otorhinolaryngology: Head and Neck Surgery, University of Michigan Comprehensive Cancer Center, University of Michigan Health System, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA
Search for other papers by Laura Fugazzola in
Google Scholar
PubMed
Search for other papers by Yuichi Ando in
Google Scholar
PubMed
Search for other papers by Yasuhisa Hasegawa in
Google Scholar
PubMed
Search for other papers by Do Joon Park in
Google Scholar
PubMed
Search for other papers by Young Kee Shong in
Google Scholar
PubMed
Search for other papers by Johannes W A Smit in
Google Scholar
PubMed
Search for other papers by John Chung in
Google Scholar
PubMed
Search for other papers by Christian Kappeler in
Google Scholar
PubMed
Search for other papers by Gerold Meinhardt in
Google Scholar
PubMed
Search for other papers by Martin Schlumberger in
Google Scholar
PubMed
Search for other papers by Marcia S Brose in
Google Scholar
PubMed
-scale trial in patients with RAI-refractory DTC, may provide insight into the management of patients receiving sorafenib in this setting. Here we report a detailed, by-cycle analysis of the incidence, prevalence, and severity of the most commonly reported and